The two-year shortage of Eli Lilly’s blockbuster weight-loss and diabetes drugs is over, the U.S. Food and Drug ...

The removal of Zepbound and Mounjaro from the regulator’s shortage list could lead to restrictions on pharmacies making ...

The San Francisco telehealth company had capitalized on the shortage by making copycat versions of popular brand-name GLP-1 ...

Hims & Hers Health shares tumbled Thursday after the Food and Drug Administration said Eli Lilly's popular weight-loss drugs ...

Eli Lilly's weight-loss drug Zepbound and diabetes medication Mounjaro are no longer in short supply. That could limit ...

Eli Lilly & Co.’s blockbuster weight-loss and diabetes drugs are no longer considered to be in shortage in the U.S., ...

Eli Lilly's weight-loss drug Zepbound and diabetes drug Mounjaro are no longer in shortage, the U.S. Food and Drug ...

The U.S. Food and Drug Administration said Eli Lilly’s diabetes and weight-loss drugs marketed as Zepbound and Mounjaro are ...

England's National Health Services plans to offer Eli Lilly's weight-loss drugs to nearly a quarter million people as part of ...

The shortage of Eli Lilly’s (LLY) blockbuster diabetes and weight loss drugs is officially over, according to the U.S. Food ...

Nearly 250,000 people in England could be taking Eli Lilly & Co.’s blockbuster weight-loss drug Mounjaro within three years ...

Eli Lilly said Wednesday it will invest $4.5 billion to build an advanced pharmaceutical drug manufacturing and development ...